Outcomes with Avelumab Maintenance Treatment for Advanced Urothelial Cancer in a US Patient Cohort
Current Oncology · 2026
DOI: 10.3390/curroncol33030138 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Oncology, 2026. Verfasst von Kenneth Carson und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Division of Hematology/Oncology, Northwestern University Feinberg School of Medicine, Arkus Professional Building, 6…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Immunological, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Merck (CrossRef Funder ID: 10.13039/100009945) and was previously conducted under an alliance between Merck and Pfizer., Merck.
Abstract (Originalsprache)
Background
This study describes treatment patterns and clinical outcomes in patients with advanced urothelial carcinoma (aUC) in the US following the approval of avelumab for first-line maintenance treatment.
Methods
This retrospective cohort study used deidentified patient data from the Tempus database. Eligible patients had completed first-line systemic anticancer treatment for aUC between July 2020 and March 2023.
Results
In total, 974 eligible patients were identified; most (72%) were male. Median age at diagnosis was 70 years. Among patients who completed first-line platinum-based chemotherapy (644 [66%]), 574 (89%) had no evidence of disease progression. Of 219 patients who received first-line maintenance, 135 (62%) received avelumab. Median (95% CI) overall survival (OS) and progression-free survival (PFS) from avelumab maintenance start were 14.9 months (13.1—not estimable [NE) and 6.4 months (4.6—NE), respectively. Enfortumab vedotin (EV) was the most common second-line treatment after avelumab (70%). Median (95% CI) OS and PFS from second-line EV start were 11.6 months (6.1—NE) and 6.6 months (4.1—NE), respectively.
Conclusions
Results provide insights into the impact of avelumab first-line maintenance treatment in patients with aUC in the US. Effectiveness data are consistent with previous findings, supporting the use of avelumab maintenance in patients without disease progression following first-line platinum-based chemotherapy. Second-line EV after progression on avelumab maintenance had similar effectiveness to results from other real-world studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Division of Hematology/Oncology, Northwestern University Feinberg School of Medicine, Arkus Professional Building, 676 N. St. Clair St., Suite 850, Chicago, IL 60611, USA.
- Merck Healthcare KGaA, 64293 Darmstadt, Germany.
- EMD Serono, Inc., 200 Pier 4 Blvd., Boston, MA 02210, USA, an affiliate of Merck KGaA.
- Tempus AI, Inc., 600 W Chicago Ave., Suite 510, Chicago, IL 60654, USA.
ORCID-Profile: Kenneth Carson, Stamatina Fragkogianni
Förderung
- Merck (CrossRef Funder ID: 10.13039/100009945) and was previously conducted under an alliance between Merck and Pfizer.
- Merck
Zitieren
APA
Carson, K., Mahmoudpour, S. H., Ike, C., Monzon, S., Fragkogianni, S., & Kearney, M. (2026). Outcomes with Avelumab Maintenance Treatment for Advanced Urothelial Cancer in a US Patient Cohort. Current Oncology. https://doi.org/10.3390/curroncol33030138
Vancouver
Carson K, Mahmoudpour SH, Ike C, Monzon S, Fragkogianni S, Kearney M. Outcomes with Avelumab Maintenance Treatment for Advanced Urothelial Cancer in a US Patient Cohort. Current Oncology. 2026. doi:10.3390/curroncol33030138
BibTeX
@article{Carson2026,
author = {Carson, Kenneth and Mahmoudpour, Seyed Hamidreza and Ike, Chiemeka and Monzon, Sebastian and Fragkogianni, Stamatina and Kearney, Mairead},
title = {Outcomes with Avelumab Maintenance Treatment for Advanced Urothelial Cancer in a US Patient Cohort},
journal = {Current Oncology},
year = {2026},
doi = {10.3390/curroncol33030138}
}
EUVIMED